Editors' Desk
-
FBI Insights On Counterfeit Drug Prevention
9/18/2015
A former FBI agent shares his tips for protecting your products from counterfeit activity.
-
Key Trends, Cross Pollination Drive Pharma EXPO
9/15/2015
Pharma EXPO is right around the corner. Discover the key industry trends that directly influenced this year’s conference program and how the event provides a unique opportunity for pharmaceutical professionals to learn from other industries.
-
Pharma Needs A Medication Adherence Game Plan
9/14/2015
Medication nonadherence is a disturbing trend that has a negative effect on patient wellness, hospital costs, and pharmaceutical manufacturer revenue. Drugmakers need to drive improvements in this area and big data, sensor technology, and a new approach to marketing can help.
-
Keeping Current With The Cold Chain
9/11/2015
Meeting the temperature-control needs today’s life science products requires manufacturers to balance regulatory compliance with quality and cost. Discover how the 13th Annual Cold Chain Global Forum can provide you with the insight necessary to succeed.
-
3 Can’t-Miss Sessions At Pharma EXPO 2015
9/3/2015
Pharma EXPO 2015 offers several educational opportunities to choose from, but these three sessions alone could be worth the trip to Vegas.
-
Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?
9/1/2015
Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?
-
Shaping The Emerging Biosimilars Landscape
8/26/2015
The emergence of biosimilars in the U.S. will undoubtedly have a marked impact on the pharmaceutical industry, but the market is young and malleable. Pharmaceutical manufacturers currently have a unique opportunity to shape perceptions and use of biosimilars among healthcare providers and their patients.
-
Making The Switch To Single-Use: Have You Thought Of Everything?
8/19/2015
In 2014, Prolong Pharmaceuticals followed through with a decision to build a facility for the scale-up of their lead product, SANGUINATE. As part of this decision, the new facility would not utilize Prolong’s traditional manufacturing process and would instead switch to one that uses single-use technology (SUT) almost exclusively. Chuck Hart, Prolong’s director of manufacturing, recently sat down with me to discuss some areas he feels are sometimes overlooked when switching from traditional stainless steel to SUT.
-
Is Sustainability Possible With Single-Use Technology?
8/12/2015
At this point, it is well known that single-use technology (SUT) can offer many benefits to a manufacturer and their facility. However, there are concerns that single-use technology produces too much harmful waste to achieve sustainability. But is this true?
-
Could Birth Of “Big Generic” Be Foreshadowing “Big Biosimilar?”
8/12/2015
In 2015, the generics market saw several players jump ship and one company grow significantly — and to some, alarmingly — larger. If buyers are consolidating and causing generics companies to consolidate, isn’t it natural to expect a similar trend to hit the biosimilars market when it’s more established?